retatrutide approval status october 2025 The FDA has issued warning letters to multiple companies marketing compounded The Retatrutide You're Seeing Online

Overall good stuff

Saxenda is a prescription-only medicine, not a cosmetic injectable

Short-chain fatty acids mediate gut microbiota-brain communication and protect the blood-brain barrier integrity

Retatrutide (LY3437943): Educational Overview Executive Summary Retatrutide is an investigational triple-agonist incretin therapy activating: GLP-1 receptors GIP receptors glucagon receptors This multi-pathway engagement affects: appetite regulation insulin signaling lipid metabolism hepatic glucose handling energy expenditure References: Coskun T et al., Cell Metabolism , 2022 Jastreboff AM et al., NEJM , 2023 Mechanism of Action GLP-1 Receptor Activation GLP-1 signaling: increases glucose-dependent insulin secretion slows gastric emptying activates satiety pathways in the brain Reference: Drucker DJ, Cell Metabolism , 2018 GIP Receptor Activation GIP signaling: enhances insulin secretion improves adipocyte insulin sensitivity modulates lipid metabolism References: Finan B et al., Nature Medicine , 2013 Nauck MA et al., Diabetes Care , 2021 Glucagon Receptor Activation Retatrutide uniquely activates glucagon receptors